Livzon Pharmaceutical Group Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
9/10
|
10 | 35.42 | -71.76% | 14.78 | -32.33% |
| P/S |
|
1.57 | 7.59 | -79.28% |
|
|
| P/BV |
|
1.32 | 3.68 | -64.09% |
|
|
| P/FCF |
|
12.28 | 55.3 | -77.79% |
|
|
| Ev/Ebitda |
|
9.16 | 2.91 | 215% |
|
|
| Ev/S |
|
1.8 | 23.72 | -92.42% |
|
|
| Ev/FCF |
|
9.2 | 63.78 | -85.58% |
|
|
| E/P |
|
0.0655 | 0.0326 | 100.73% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
7/10
|
24.39 | -11.9 | -304.93% | 23.42 | +4.14% |
| ROE |
|
14 | 5.19 | 169.84% |
|
|
| ROA |
|
7.83 | 3.47 | 125.64% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
15.72 | -11.49 | -236.85% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
8/10
|
1.31 | 0.7755 | 69.56% | 1.4 | -5.85% |
| Nеt Debt/Ebitda |
|
0 | 0.0127 | -100% |
|
|
| Debt/Ratio |
|
0.1617 | 0.1229 | 31.63% |
|
|
| Debt/Equity |
|
0.8473 | 0.776 | 9.19% |
|
|
| Debt/Net Income |
|
2.07 | 1.76 | 17.95% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
10/10
|
13.61 | 5.7 | 138.78% | 6.85 | +98.68% |
| Number of years of dividend growth |
|
3 | 1.13 | 166.67% | ||
| DSI |
|
0.8571 | 0.5838 | 46.82% |
|
|
| Average dividend growth |
|
-0.3471 | 3.2 | -110.84% |
|
|
| Average percentage for 5 years |
|
6.85 | 4.95 | 38.32% |
|
|
| Average percentage for payments |
|
44.64 | 23.96 | 86.29% |
|
|
| Difference from average difference in sector |
|
7.91 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
5/10
|
32.45 | 28.69 | 13.11% | ||
| Growth impulse Ebitda in 5 years |
|
22.68 | -40.52 | -155.97% | ||
| Growth impulse Net Income in 5 years |
|
49.95 | 94.84 | -47.33% | ||
| Growth impulse FCF in 5 years |
|
77.37 | 91.41 | -15.36% | ||
| Growth impulse EPS in 5 years |
|
40.97 | -118.14 | -134.68% |
IP Score
6.69/10
